Peripheral Antagonist News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Patients in the KarXT (xanomeline–trospium) group reported a significant reduction in Positive and Negative Syndrome Scale (PANSS) score compared to those in the placebo group. 2. Majority of adverse events were mild-to-moderate, with no treatment-related fatalities or increase in extrapyramidal motor symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Current antipsychotic therapies for schizophrenia

Posted on 7565 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that results from the EM...

Phase II results appear promising for a new combination treatment for schizophrenia. Findings from previous studies have shown that the muscarinic receptor agonist xanomeline could be used as a novel way to treat psychosis that patients experience during both Alzheimer's disease and schizophrenia, but there has been concern about the accompanying severe gastrointestinal side effects, including vomiting, nausea, and diarrhea. For the new trial, researchers from Karuna Therapeutics in Boston decided to pair xanomeline with another drug, trospium, an antagonist of muscarinic receptors. Steven Pa...